ReviewDrugs2018
Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.
Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.Signal transduction and targeted therapy · 2026Trial
- Management Strategies and Outcomes in HR+/HER2- Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent Therapies.Breast cancer (Dove Medical Press) · 2025Article
- Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism.Journal of nanobiotechnology · 2024Article
- Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Cardiac Toxicity From Adjuvant Targeting Treatment for Breast Cancer Post-Surgery.Frontiers in oncology · 2022Review
- Decoding the Therapeutic Implications of the ERα Stability and Subcellular Distribution in Breast Cancer.Frontiers in endocrinology · 2022Review
- Proteolysis-targeting chimeras and their implications in breast cancer.Exploration of targeted anti-tumor therapy · 2021Review
- Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives.Breast cancer (Dove Medical Press) · 2020Review
- Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence.Cancer management and research · 2018Review
- A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis.OncoTargets and therapy · 2018Review
- Efficacy and Safety ofIntegrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fulvestrant (Faslodex
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.